RO7247669

PreclinicalSmall molecule

Roche

RO7247669 is one of 53 small molecule programs targeting Solid Tumor. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorActive, not recruiting

Metastatic Solid TumorsActive, not recruiting

Solid TumorPreclinical

Active, not recruiting

Metastatic Solid TumorsPreclinical

Active, not recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

DATROWAY

Daiichi Sankyo

Preclinical

1 2

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 3

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

2 4

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 5

Navmi

SSummit Therapeutics

Preclinical

1 6

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 8

Tulmimetostat

Novartis

Preclinical

1 9

PD-1 Inhibitor

Johnson & Johnson

Preclinical

1 10

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalActive, not recruiting

Solid Tumor

NCT04140500

Clinical

Trials by Indication[1]

Metastatic Melanoma1 trial

A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma

Completed· Roche logo

Roche·Phase 2·NCT05419388·93 enrolled

Melanoma1 trial

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

Completed· Roche logo

Roche·Phase 1/2·NCT05116202·110 enrolled

Solid Tumor1 trial

An Open Label, Multicenter, Dose Escalation, Phase 1 Study to Evaluate Safety/Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti Tumor Activity of RO7247669, a PD1-LAG3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors

Active, not recruiting· Roche logo

Roche·Preclinical·NCT04140500·170 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for RO7247669. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RO7247669 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RO7247669. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Roche

RO7247669

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Metastatic Melanoma1 trial

Melanoma1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News